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ABSTRACT
Few studies were conducted investigating the immunological profiles in gastrointestinal stromal tumors
(GIST). Adaptive and innate immune cells are present in the tumor microenvironment, indicating GIST as
inflamed tumors. In addition, murine models suggested a potential interaction between immune
components and imatinib. In this retrospective study, the GIST immunological profile was investigated
through in silico analysis and immunohistochemistry (IHC), exploring the basis for immunotherapy
approaches. Gene expression profiles (GEP) from 31 KIT/PDGFRA-mutant GIST were analyzed to evaluate
the tumor microenvironment and immunotherapy predictive signatures such as the expanded IFN-γ-
induced immune signature (EIIS) and the T-cell-inflamed signature (TIS). GEP and IHC supported the
presence of immune infiltrate in GIST, with dominance of CD4+ and CD8+ T cells and M2 macrophages
showing a remarkable similarity with melanoma microenvironment. The EIIS genes were expressed in
most of GIST samples and positively correlated with PD-L1 abundance (p < .0001). Co-expression was
also found between PD-L1 and CD8A (p < .0001) or CD8B (p = .0003). Moreover, the median TIS score for
GIST was between the 65th and 70th percentile of the Cancer Genome Atlas dataset, in the same range
of tumors responding to anti-PD-1/PD-L1. Analysis of the Gene Expression Omnibus database GIST
samples pre- and post-treatment confirmed that imatinib downregulates PD-L1 and IRF1 expression
through the inhibition of KIT and PDGFRA, thus contributing to counteract the suppressed adaptive
immune response against GIST. The presence of a rich immune infiltrate in GIST along with the presence
of TIS and EIIS suggests that GIST may benefit from immunotherapy along with tyrosine kinase
inhibitors.
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Introduction
Gastrointestinal stromal tumors (GIST) are rare mesenchymal
tumors characterized in the vast majority of cases by muta-
tions of KIT proto-oncogene (KIT) and Platelet derived
growth factor receptor alpha (PDGFRA) genes that are targets
of tyrosine kinase inhibitors (TKI). The TKI revolutionized
the treatment strategy of GIST and dramatically improved the
clinical outcomes of patients with advanced disease.1–3
Unfortunately, even imatinib-responder patients invariably
develop treatment resistance. A second generation of TKI,
sunitinib and then regorafenib, targeting also kinases involved
in tumor-related angiogenesis, was developed and approved
for imatinib-refractory GIST treatment. However, the benefit
of these second and third generations of TKI is very limited
because patients again develop resistance after a median time
of 4–6 months. Recently, new pan-TKI inhibitors demon-
strated good and interesting results in the prolongation of
survivals in early phase trials.4,5 However, the molecular back-
ground of GIST resistant to TKI is very complex due to the
acquisition of new mutations and several genome alterations.
Patients’ prolonged life expectancy associated with the com-
plex biology involved in progressive disease led to a growing
urgency and interest in developing new strategies to overcome
the TKI resistance.
Recently, the introduction of immunotherapy in oncology
with the monoclonal antibodies against the immunological
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checkpoints PD-1 and CTLA-4 revolutionized the treatment
of cancer improving survival rates.6–8 Many studies on pre-
dictive factors of treatment response such as PD-1/PD-L1
expression, tumor mutational burden (TMB), immunogenic
antigens or tumor-infiltrating immune cell presence and acti-
vation are under evaluation.
Only few studies, in preclinical and clinical setting, were
conducted investigating the immunological profile of GIST.
Available data showed that tumor-infiltrating immune cells
are present in GIST, and seem to play a role in disease out-
come and in increasing the antitumor activity of imatinib. In
a transgenic mouse GIST model imatinib could polarize
tumor-associated macrophages (TAM) to an M2-like
phenotype.9 The TAM was described in the microenviron-
ment of GIST, in particular M2 macrophages were most
enriched in metastatic and in imatinib-treated cases.9–11
Imatinib can promote natural killer (NK) activation and
IFN-γ production, through stimulation of a KIT-dependent
cross-talk between host dendritic cells and NK.11 In particu-
lar, the NK infiltrate predicts progression-free survival in
GIST, and patients classified as immunological responders
on the basis of NK-interferon levels showed a better survival
while treated with imatinib.12
Tumor-infiltrating lymphocytes (TIL) are the second most
enriched immune cell population in GIST samples.9,11,13,14
Balachandran et al. demonstrated that CD8+ T cells contribute
to antitumor effects of imatinib.15 They showed that imatinib
leads to the activation of CD8+ T cells and inhibition of Treg
through the inactivation of indoleamine 2,3-dioxygenase 1 (IDO).
In preclinical GIST murine model, it was also shown that the
therapeutic efficacy of imatinib was increased by combination
with immune checkpoint inhibitors.16 Few data on PD-1/PD-L1
expression in GIST are available showing that PD-L1 tumor
expression by immunohistochemistry (IHC) was higher in GIST
than in other sarcoma and PD-L1 expression at the mRNA level
was heterogeneous across tumors.13–17
With regard to GIST patients, a clinical trial on the combina-
tion of KIT and CTLA-4 blockade with dasatinib and ipilimu-
mab in GIST reported no synergistic activity, but the number of
patients was limited to derive any conclusion.18 The aim of this
retrospective study was to dissect the immunological landscape
of GIST to provide further rationale for immune-based approach
and eventually develop basis to improve the treatment of GIST.
Results
GIST immune microenvironment
The abundance of 22 immune cell types within the tumor-
infiltrating leukocyte population was estimated on 31 GIST
retrospectively collected samples, in which gene expression pro-
files (GEP) were previously obtained with microarray (19 sam-
ples) and RNA-seq (12 samples) techniques. The two
independent deconvolution analyses highlighted the prevalence
of T cells, both CD4+ and CD8+, andmacrophages (M2 andM1)
(Figure 1a,b and Supplementary Table S1). Overall, the absolute
abundance estimation of tumor-infiltrating cells revealed some
degree of variability, not due to the different molecular classes
(KIT of PDGFRA mutant, Supplementary Figure S1A). It was
also clarified that the two methods employed for immune cell
deconvolution (microarray and RNA-seq) are actually compar-
able since variability found did not depend on the type of plat-
form employed to perform the gene expression quantification
(Supplementary Figure S1B) and Cibersort results obtained with
the two methods on the same samples are highly correlated
(Pearson r = 0.82–0.89) and cluster together (Supplementary
Figure S2).
Examining the relative abundance of the single hematopoietic
cell types (Supplementary Table S2), significant correlations
between pairs of subpopulations could be identified. In particular,
the abundance of macrophages negatively correlated with T cells
presence (CD4+ and CD8+ together) supporting the existence of
a reciprocal balance between the myeloid and lymphoid compo-
nents of the immune infiltrate at the tumor site (Supplementary
Figure S3). The comparison of the global GIST immune profile
with that of other solid tumor types showed remarkable similarity
to that of melanoma, one of the tumors that mostly benefits from
immunotherapeutic approaches (Figure 2a). The immune micro-
environment of GIST display a high abundance of
infiltrating CD8+ T cells, similarly to primary and metastatic
melanoma, where it is known to be particularly enriched. This
evidence was also supported by other unsupervised approaches
like the principal component analysis (PCA) (Figure 2b).
The IHC characterization corroborated the significant pre-
sence of an intra- and peri-tumoral immune infiltrate in GIST
samples, consisting mostly of CD8+ T cells and CD163+ M2
macrophages (Figure 3, Supplementary Table S3). The num-
ber of CD8+ lymphocytes and CD163+ elements varied from
5.6 to 88.9 mm2 (median 17.5 mm2) and 4.9 to 49 mm2
(median 27.2 mm2) respectively (Supplementary Table S3).
These CD8+ and CD163+ immune populations were also
observed at the invasive margin of the tumors
(Supplementary Table S3). Expression of Tia-1 was also
found in agreement with the presence of active cytotoxic
elements (mainly located between neoplastic cells)
(Supplementary Table S3) (Figure 3). NK CD16+/granulysin-
(GNLY)+ were also detected in most of the GIST samples (5/
8) both in the core and in the invasive margin of the tumors
(Supplementary Table S3) (Supplementary Figure S4). Intra-
tumoral FOXP3+ T-regulatory lymphocytes were revealed in
4/8 of the cases. Furthermore, the IHC study showed a PD-L1
protein expression on neoplastic cells in 50% of the samples
analyzed (score +2) (Supplementary Table S3).
GIST express immune signatures predictive of immune
checkpoint inhibitor response
Beyond the estimation of tumor-infiltrating cells abundance,
GEP were also interrogated in order to evaluate the expression
in the 31 GIST samples of the expanded IFN-γ-induced
immune signature (EIIS), identified as a predictor of immu-
notherapy response in head and neck squamous cell carci-
noma and melanoma (Supplementary Table S4).19,20 This
signature encompasses 18 genes related to cytolitic activity,
inflammatory cytokines, T-cell markers, antigen presentation,
and immunomodulatory factors. We found that this signature
was clearly expressed in the majority of GIST samples and,
interestingly, it positively correlated with PD-L1 expression
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(p < 0.0001) (Figure 4a,b). Interestingly, even in melanoma
samples from the Cancer Genome Atlas (TCGA), the EIIS
signature correlates with PD-L1 expression (Supplementary
Figure S5).
Moreover, the PD-L1 transcript abundance also positively
correlated with the expression of CD8 receptor alpha and beta
chains (respectively p < 0.0001 and p = 0.0003) that are
expressed on cytotoxic T cells (Figure 4c). Of note, a good
Figure 1. Heatmap representing the composition of the immune infiltrate signatures by microarray (a) and RNA-seq (b) data with CIBERSORT analysis (absolute
abundance). Hierarchical clustering was performed on the infiltrating immune populations using Euclidean distance as a metric of similarity and average linkage as
clustering method. The gray bars indicate the total absolute score for each sample. KIT- and PDGFRA-mutant GIST are labeled in cyan and yellow respectively. Tissue
samples are labeled in green for primary tumors and purple for metastasis. The tumor site instead is represented with pink and brown boxes for stomach and
intestine respectively.
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average expression of PD-1 (6.05 ± 0.04 log2Signal by micro-
array; 0.68 ± 0.1 tpm by RNA-seq) was found in all samples,
supporting the hypothesis that GIST could be a good candi-
date for novel immune checkpoint treatments.
Gene expression data were also exploited to investigate
another immune signature related to clinical response to
checkpoint inhibitor treatments. In particular, we focused
also on the T-cell-inflamed signature (TIS) proposed by
Ayers et al. as an improvement of the EIIS described above.
This signature (characterized by markers of an active IFN-γ
signaling, cytotoxic effector molecules, antigen presentation
and T-cell active cytokines) measures the presence of
a suppressed adaptive immune response and was previously
shown to be enriched in patients responsive to PD-1 inhibitor
treatment (Supplementary Table S5).19,20
Adopting the TIS algorithm,19 we compared the TIS score
between our series and other tumors from TCGA dataset
(Supplementary Table S6) showed that GIST have a high median
TIS score (8.22), very close to tumor types with the highest
response rates to anti-PD-1/PD-L1 inhibitors, such as head and
neck squamous cell carcinoma (8.10), lung squamous cell carci-
noma (8.26), and kidney clear cell carcinoma (8.79) (Figure 5).
Imatinib downregulates PD-L1 expression in GIST
samples
Since the current medical treatment of GIST relies on multi-
ple and different generations of TKI, it is mandatory that any
new treatment approach is conceived in combination with
a TKI. It is already known that imatinib can exert immune
Figure 2. (a) Unsupervised hierarchical clustering of the tumor-infiltrating composition of GIST and other solid tumor types. The heatmap shows that CD8+ T cells are
particularly enriched in GIST and melanoma (primary and metastatic). (b) Principal component analysis of CIBERSORT results of GIST (in purple) and other solid
tumors.
Figure 3. Immunohistochemical characterization of GIST samples. In the upper row, one high-CD8+ GIST shows high number of Tia-1+ (x100) (inset: x400) cell of
microenvironment, presence of M2 CD163+ macrophages (x100) (inset: x400), and PD-L1 positivity (x100) (inset: x400) in the neoplastic population. The lower row
shows one low-CD8+ sample that is characterized instead by a very low number Tia-1+ (x100) cells, presence of M2 CD163+ macrophages (x100), and PD-L1
negativity (x100) in the neoplastic population. The comparison between the two GIST groups high-CD8+ versus low-CD8+ highlights significant differences in the CD8
and TIA1 proteins expression (p = 0.01 and p = 0.02 respectively); differently, there are no significant differences in terms of CD163 and PD-L1 (p = 0.37 and p = 0.71
respectively).
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modulatory effects, that PD-1/PD-L1 blockade enhances the
antitumor efficacy of imatinib in murine GIST model,16 and
that JAK inhibitors and imatinib decrease the expression of
PD-L1 in vitro in GIST882 and GIST-T1 cell lines. We there-
fore explored the possible modulatory effect of imatinib on
the expression of the immune checkpoint inhibitors targets in
a The Gene Expression Omnibus database (GEO) dataset of
GIST tumor samples pre- and post-imatinib treatment. Since
there are already evidences that KIT and PDGFRA interact
with STAT1,21,22 it is conceivable that their signaling may
regulate the expression of PD-L1 through the phosphorylation
of STAT1 and the upregulation of IRF1, as it was described in
melanoma.23 Analysis conducted on public available GIST
data showed that IRF1 and PD-L1 were significantly repressed
in imatinib-treated with respect to pre-treatment samples
(Figure 6). Together with the previous knowledge reached
by in vitro studies, these data from patient samples confirmed
the hypothesis of a repressive role of imatinib on PD-L1
expression, supporting a view in which both TKI and check-
point inhibitors cooperate in the activation of an adaptive
immune response against GIST.
Discussion
A comprehensive immunological evaluation of GIST showed
a significant presence of immune infiltrate in GIST samples,
with a predominance of T cells, both CD4+ and CD8+, and
M2 macrophages. This immune profile emerges as closely
similar to that of other solid tumor types in particular of
melanoma, one of the most striking clinical responders to
immunotherapy. The CD4+ and CD8+ expression patterns
were slightly different from the previously published report
by D’Angelo S. et al., in which it is mainly with a percentage
<5%. The same report documented the presence of a high
percentage of FOXP3+ cells, and of PD-L1 expression,
Figure 4. (a) Heatmap representing the positive correlation between the expanded IFN-γ-induced immune signature and PD-L1 expression (cyan bars) in GIST
sample. (b) Scatterplot between the average expression of the EIIS per sample and the PDL1 expression. (c) Positive correlation between PD-L1 and both CD8A and
CD8B expressions.
Figure 5. T-cell-inflamed signature score of GIST and other solid tumor types from TCGA. ACC: adrenocortical carcinoma; BLCA: bladder urothelial carcinoma; BRCA:
breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma;
DLBC: lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: esophageal carcinoma, GBM: glioblastoma multiforme; HNSC: head and neck squamous cell
carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: acute myeloid leukemia; LGG: brain
lower grade glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma, MESO: mesothelioma; OV: ovarian serous
cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: pheochromocytoma and paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarci-
noma; SARC: sarcoma; SKCM: skin cutaneous melanoma; STAD: stomach adenocarcinoma; TGCT: testicular germ cell tumors; THCA: thyroid carcinoma; THYM:
thymoma (THYM); UCS: uterine carcinosarcoma; UVM: uveal melanoma.
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positively correlated with higher amounts of infiltrating CD8+
or CD3+ cells, suggesting that these T cells may be function-
ally deficient due to the upregulated inhibitory receptor
expression.14 The different number of cases and probably
also the different quantification methods may have contribu-
ted to the slight discrepancy of some subsets of immune cells.
Anyway, notwithstanding this little different amount of TILs,
altogether these data demonstrate that TILs are present in
GIST and that the immune cell infiltrate may be considered
a feature of GIST.13
In fact, a recent work by Vitiello A et al.24 on the immune
profiling of GIST reported a difference of immune cell infil-
trate, immunological activity and expression of immune-
related genes between PDGFRA- and KIT-mutant GIST.
Moreover, another recent study reported the expression of
PD-L1 in around 70% of GIST, and identified an association
between the expression of PD-L1 and tumor size.25 In our
series, there was no clear correlation between TIL amount and
clinical and tumor features, and the limited number of sam-
ples did not allow to derive clinical correlations from the
study results.
Additionally, an relevandata resulting from our work is the
expression in GIST tumor samples of gene signatures, both
the EIIS and TIS, that were recently identified as predictors of
immune checkpoint inhibitors response in multiple tumor
types. The EIIS was clearly expressed in the majority of
GIST samples and, interestingly, it positively correlated with
PD-L1 expression. This signature was considered a predictor
of immunotherapy response in head and neck squamous cell
carcinoma, melanoma, and gastric cancer.19,20 Indeed, it is
known that PD-L1 expression is directly induced in tumor,
immune infiltrate, and stromal cells by sustained IFN-γ sig-
naling, representing feedback inhibition of anti-tumor
immune responses. Few studies addressed the PD-1/PD-L1
expression in GIST and the available data showed that PD-L1
tumor expression by IHC was higher in GIST than in other
sarcomas and PD-L1 expression at the mRNA level was het-
erogeneous across tumors.14,17 In fact, tumor heterogeneity
could have an impact on the evaluation of the tumor immune
microenvironment; therefore, we included in the analysis
a representative number of tumor tissues, considering that it
is a rare tumor, and also performed data validation by IHC on
formalin-fixed paraffin-embedded (FFPE) samples, scoring
different areas of the tumor specimen.
In our series, we found a positive correlation between the
EIIS and PD-L1 expression and a positive correlation between
PD-L1 expression and CD8A/CD8B genes supporting an
adaptive mechanism of immune escape, as described in
other oncological settings.
In addition, GIST showed high expression of the TIS signa-
ture and therefore high values of TIS score that were very close to
tumor types in which high rates of response to PD-1/PD-L1
inhibitors were seen. The TIS score was recently evaluated
together with the TMB to assess the predictive power in clinical
response to anti-PD-1/PD-L1 therapy, stratifying human can-
cers into different clusters26 capturing independently distinct
tumor and microenvironment features.
Finally, in vitro (GIST882 and GIST-T1 cell lines) and in vivo
murine models showed that IFN-γ regulates PD-L1 expression
by the activation of the JAK-STAT signaling. Indeed, the
induced upregulation of PD-L1 was abolished with imatinib
and PD-1/PD-L1 blockade enhanced T-cell activity and
increased the antitumor effects of imatinib.16 This is in agree-
ment with the evidences accumulating on other driver onco-
genes and tumor histotypes, where for example oncogenic RAS
signaling contributes to the evasion from the host immune
system through upregulation and stabilization of PD-L1 that
can be reversed by MEK inhibitor treatment.27,28
Indeed, multiple reports have shown that imatinib has an
immune-modulatory effect, ranging from the increase in the
number and activation of CD8+ T cells and NK cells to the
decrease of Tregs and of IDO expression in the tumor.13,15,29–
31 Moreover, imatinib can synergize with immunotherapy
since the treatment with anti-PD-1 or anti-PD-L1 in the Kit
V558Δ/+ GIST murine model increases the effect of imatinib by
enhancing CD8+ T-cell function.16
The results of our study on the presence of the immune
microenvironment in GIST along with the expression of spe-
cific signatures, that are known to be predictive of response to
checkpoint inhibitors, suggest that GIST may benefit from
immunotherapy together with TKI.
The study on the combination of KIT and CTLA-4 block-
ade with dasatanib and ipilimumab reported a limited clinical
efficacy of this combination in GIST but, as the authors
stated, the enrolled patients were extensively pretreated and
most of them were not evaluable for response.18 Definitely,
novel immunological approaches are emerging that exploit
Figure 6. IRF1 and PD-L1 normalized expression between pre- and post-imatinib
-treated GIST samples of the GEO dataset GSE15966.
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different immunomodulatory molecules to synergize with
imatinib. One strategy could be to target the M2 macrophages
polarization through the use of anti-CD40 antibody or TLR3
agonist or other compounds able to revert the M2-like phe-
notype induced by KIT inhibition.32 Future clinical trials with
new and more effective checkpoint inhibitors and IDO inhi-
bitors in selected patients should be encouraged. In fact,
despite new TKIs, BLU285, DCC2618, and crenolanib
demonstrated good and interesting results in the prolongation
of survival in early phase trials,4,5 in the future it is expected
that TKI resistance develops and thus more efforts are needed
to find a cure beyond or along with TKI for long-term
advanced GIST.
In conclusion, our study provides a comprehensive picture
of the microenvironment in GIST with a rich immune infil-
trate in the majority of GIST along with the presence of TIS
and IFN-γ signatures, predictive of immunotherapy response
in multiple tumors, suggesting a potential susceptibility to
respond to PD-1/PDL1 inhibitors and adds new data useful
to build a robust basis for an immunotherapy approach in
GIST treatment.
Patients and methods
Patients and tumor samples
A total of 31 GIST tumor samples were retrospectively col-
lected and analyzed. The tumor and clinical characteristics are
reported in Table 1. All cases were revised by two pathologists
with expertise in GIST diagnosis, and all samples were char-
acterized by the presence of KIT or PDGFRA mutation. KIT/
PDGFRA WT GIST cases were excluded. Twenty-six samples
were from primary tumors and five from metastases. In 26/31
patients, the analysis was done in absence of TKI therapy and
only in 5 patients after TKI therapy (2 cases after imatinib and
3 cases after imatinib and sunitinib). Fresh tumor tissue was
snap-frozen in liquid nitrogen and stored at −80°C until RNA
extraction. In 19 specimens, the analysis was done on HG-
U133Plus 2.0 Affymetrix arrays while in 12 tumors by Whole-
Transcriptome RNA Sequencing on Illumina platform. This
study was performed in agreement with the Declaration of
Helsinki and approved by the local institutional ethical com-
mittee of Azienda Ospedaliero-Universitaria Policlinico
S.Orsola-Malpighi (approval number 113/2008/U/Tess).
All patients provided written informed consent.
Gene expression analysis
Whole transcriptome sequencing and microarray samples
were previously analyzed in Nannini et al.33 In detail,
RNeasy Mini Kit (Qiagen, Milan, Italy) was employed to
extract the total RNA from tumor specimens. For the RNA-
seq samples, the cDNA libraries were synthesized starting
from 250 ng total RNA with TruSeq RNA Sample Prep Kit
v2 (Illumina, San Diego, CA, USA) following the manufac-
turer’s protocol. HiScanSQ sequencer (Illumina) was used to
generate sequences at 75bp in paired-end mode yielding an
average of 61 million mapped reads/sample, reaching an
average coverage of 44X. Read pairs were mapped on refer-
ence human genome and the gene expression was quantified
using kallisto adopting the transcript per million (TPM)
normalization.34 For microarray samples, the RNA was qual-
ity-controlled and labeled as indicated by the Affymetrix
expression technical manual and then hybridized to HG-
U133Plus 2.0 arrays. Gene expression data were normalized
Table 1. GIST samples included in series.
Sample Sex Age Tissue sample Site size MI KIT/PDGFRA mutation TKI therapy Miettinen score Platform
GIST002 F 85 Primary Stomach 8 <5 KIT exon 11 V560D No Low Microarray
GIST004 M 79 Primary Stomach 5 7 KIT exon 9 ins 502–503 No Intermediate Microarray
GIST005 M 68 Primary Stomach 7 4 PDGFRA exon 12 del/ins SPDGHE566–571RIQ No Low Microarray
GIST008 M 62 Primary Stomach 2 4 KIT exon 11 V559D No Low Microarray
GIST009 M 54 Primary Stomach 3 <5 KIT exon 11 ins TQLPYDHKWEFP 574–585 No Low Microarray
GIST011 M 77 Metastasis Stomach 20 >10 KIT exon 11 del WK557–558 Imatinib High RNA-seq
GIST012 F 66 Primary Stomach 4 <5 PDGFRA exon 14 K646E No Low Microarray
GIST013 M 46 Primary Ileum 7 <5 KIT exon 11 V559D No Low Microarray
GIST015 F 64 Primary Stomach 5.5 <5 PDGFRA exon 18 del DIMH842-845 No Low Microarray
GIST016 F 62 Primary Stomach 3.7 NA KIT exon 11 L576P No NA Microarray
GIST018 M NA NA NA >5 NA KIT exon 11 V559G No NA Microarray
GIST020 M 38 Metastasis Ileum NA NA KIT exon 11 del MYEQW552–557 NA NA Microarray
GIST022 F 76 NA Stomach NA NA PDGFRA exon18 D842V NA NA Microarray
GIST025 M 84 NA NA NA NA KIT exon 11 del/ins WKV557–559F NA NA Microarray
GIST026 M 49 Metastasis Stomach NA NA PDGFRA exon 12 V561D NA NA Microarray
GIST121 M 71 Primary Stomach 5.5 4 KIT exon 11 V559D No Low Microarray
GIST124 M 73 Metastasis Stomach 17 >10 KIT exon 11 ins 1765–1766 Imatinib and sunitinib High RNA-seq
GIST125 F 48 Primary Stomach 6 5 KIT exon 11 W557R No Low Microarray
GIST129 M 59 Primary Stomach 5 5 KIT exon 11 del/ins YEVQWKV553–559L No Intermediate Microarray
GIST130 F 79 Primary Stomach 7 >10 KIT exon 9 ins 502-503 No High Microarray
GIST131 M 68 Metastasis Ileum 6 3 KIT exon 11 del VYIDPTQLPY569-578 Imatinib and sunitinib Intermediate RNA-seq
GIST135 F 61 Primary Stomach 3.5 6 KIT exon 11 del WKVVE557-561 No Intermediate Microarray
GIST136 M 76 Primary Stomach 4.5 6 PDGFRA exon 18 D842V No Intermediate RNA-seq
GIST138 F 75 Primary Stomach 7 8 PDGFRA exon 18 D842V No High RNA-seq
GIST140 F 45 Primary Stomach 2 2 PDGFRA exon 18 D842V No Low RNA-seq
GIST142 M 68 Primary Stomach 3 5 PDGFRA exon 18 D842V No Low RNA-seq
GIST150 F 58 Primary Stomach 7 68 KIT exon 11 del PMYE551-554 No High RNA-seq
GIST165 M 51 Primary Stomach 12 <2 PDGFRA exon 18 D842V No Intermediate RNA-seq
GIST174 M 61 Primary Stomach 6 14 KIT exon 11 L576P Imatinib High RNA-seq
GIST178 F 70 Primary Stomach 10 >5 KIT exon 11 V559D No High RNA-seq
` F 62 Primary Duodenum 4 >5 KIT exon 11 del NGNNYVYIDPTQL564-576 Imatinib and sunitinib Intermediate RNA-seq
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and quantified by the RMA algorithm (package oligo,
R-bioconductor).
Bioinformatics analysis
The analytical tool CIBERSORT (Cell-type Identification By
Estimating Relative Subsets Of RNA Transcripts)35 was
applied on 31 tumors samples that were analyzed either with
Affymetrix Array (19 samples) or Illumina whole transcrip-
tome sequencing (12 samples) as described in Table 1.
CIBERSORT uses a set of 22 immune cell reference profiles
to derive a signature matrix which can be applied to decon-
volute mixed samples in order to determine relative propor-
tions of immune cells. Even if the CIBERSORT algorithm was
originally developed using microarray data, it was declared as
“platform agnostic”36 and, therefore, applicable to both
Affymetrix and Illumina data. The analysis was performed
separately for the two set of data obtained with different
techniques (microarray and RNA-seq). For each set, an unsu-
pervised hierarchical clustering analysis was adopted using the
CIBERSORT absolute estimation with the aim to evaluate the
variability of the main microenvironment cells subpopula-
tions. On the other hand, the CIBERSORT relative abundance
scores were compared between GIST and 18 different solid
tumors previously analyzed by Gentles et al.37 For this pur-
pose, we adopted the microarray subset of GIST since the
reference authors based their study as well. More specifically,
the 22 immune subpopulations were aggregated into 11 cell
classes following the representation given by Gentles et al.,37
then the similarity between GIST and other solid tumor was
evaluated applying two different unsupervised approaches: the
hierarchical clustering method and PCA (R-bioconductor,
stats package). All the hierarchical clustering were performed
adopting the ComplexHeatmap package within
R-bioconductor (distance: Euclidean, clustering method: aver-
age linkage). For both microarray and RNA-seq samples, the
transcriptome data were also used to quantify the expression
of specific signatures known to be related to the cancer
immune landscape. The transcript quantification data were
first normalized and log2 transformed either with quantile
normalization or log2TPM calculation respectively for micro-
array and RNA-seq data. An additional normalization was
performed by subtracting the arithmetic mean of ten house-
keeping gene expression (Supplementary Table S7). This
group of genes was previously identified as low variance
within a large set of cancer types and was adopted as
a normalization factor for each sample.19
The gene expression data, transformed as described
above, were used to evaluate the expression of EIIS, an 18
genes signature defined by Ayers et al. (Supplementary
Table S4). The global EIIS score for each sample was calcu-
lated by averaging the expression values of the 18 genes.
The obtained scores were correlated with the corresponding
PD-L1 expression by sample using the R package stats.
Besides EIIS, we also evaluated the TIS.19 Starting from
a larger and more diverse tumor data set spanning nine
cancer types (KEYNOTE-012 and -028 studies), the authors
defined the TIS as a 18 genes signature (Supplementary
Table S5), and basing on this improved set of genes they
determined the TIS score as a linear function defined as:
TIS ¼ Σ18
i¼1
xiwi, where xi is the ith gene’s expression value
obtained as described above and wi is a predefined weight
for the ith gene derived by Ayers et al. that were derived
from logistic regressions model.
Recently, Danaher et al. computed the TIS score adopting
the gene expression data from the tumor included in TCGA.20
Following their strategy of analysis, we evaluated the TIS score
in our GIST series with respect to TCGA cancer types.
Considering that the entire TCGA was derived from RNA-
seq as TPM (https://osf.io/gqrz9/), we referred to RNA-seq
GIST subgroup for the TIS score calculation in order to
provide consistent and comparable expression data.
Other source of open data were explored in order to
identify the effect of imatinib on PD-L1 and IRF1 expression.
In particular, the GSE15966 dataset (GEO) was adopted as
microarray expression series of 18 coupled GIST samples, pre-
and post-imatinib treatment.38 The LOESS normalized
expression data of the coupled GIST samples were obtained
with GEO2R tool and the differential expression of PD-L1
and IRF1 between pre- and post-imatinib-treated GIST was
evaluated by a paired t-test analysis.
Immunohistochemistry
Eight FFPE samples were profiled by IHC. Unstained slides
were dewaxed and rehydrated through Histoclear and graded
alcohols. For antigen retrieval, slides were incubated in a PT-
Link for 5 min at 92°C in EnVision Flex Target retrieval
solution High pH (K 8004, Dako, Glostrup, Denmark).
Incubation with the following primary antibodies was carried
for 30 min at room temperature: anti-CD8 (dilution 1:100,
clone 144b, Dako), anti-TIA-1 (dilution 1:300, clone 2G9,
Immunotech), FOXP3 (dilution 1:100, clone SP97, Abnova),
anti-CD163 (dilution 1:100 clone 10D6, Leica), and anti-PD
-L1 (dilution 1:100, clone E1L3N, Cell Signaling).
Immunostaining was performed employing the Dako Real
Detection System Alkaline Phosphatase Kit (K5005, Dako)
and chromogen (Fast Red) provided with the kit. For double
immunostainings, the following mouse monoclonal antibo-
dies were used: anti-granulysin (clone F-9, dilution1:300,
Santa Cruz, Santa Cruz Biotechnology, Inc., Texas, U.S.A)
and anti-CD16 (clone 2H7, dilution 1:40, Leica
Microsystems Ltd., Newcastle-upon-Tyne, UK) according to
the protocol described elsewhere.39
The immunostained slides were scanned at 200× magnifi-
cation by Olympus Dot-slide microscope digital system
equipped with image analysis software VS-ASW and then
evaluated in representative areas: each microenvironment
marker was separately scored both in the core of the tumor
(ten randomly selected fields) and in the invasive margin of
tumor (ten randomly selected fields); the results were first
reported as mean number of positive tumor-infiltrating
immune cells/high power field and than mathematically
referred to 1 mm2. The PD-L1 immunostaining in neoplastic
cells was scored as 1+ when <5% positive cells were counted; 2
+ when the percentage of stained cells was >5% and <50%;
and 3+ when the number of stained cells was >50%.
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